MedPath

Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma

Not Applicable
Completed
Conditions
Diffuse Large B Cell Lymphoma
Grade IIIB Follicular Lymphoma
Registration Number
NCT01715961
Lead Sponsor
Centre Henri Becquerel
Brief Summary

This clinical trial is a multicentric prospective study to assess the clinical and prognostic value of sarcopenia in patients older than 70 years with diffuse large B-cell lymphoma.

Detailed Description

Sarcopenia status is assessed by CT scan imaging on the overall survival at 18 months in patients older than 70 years with diffuse large B-cell lymphoma treated by R-CHOP.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
98
Inclusion Criteria
  • Patients >= 70 years
  • DLBCL, grade IIIB follicular lymphoma or histologically proven transformed low grade lymphoma
  • Whatever the IPI score and the performance status
  • Treated by Rituximab-CHOP or Rituximab-mini-CHOP
  • CT scan imaging performed one month or less before inclusion
  • Signed informed consent
Exclusion Criteria
  • No initial CT scan imaging performed more than one month before inclusion
  • Positivity for HCV, HBV and HIV
  • Anthracycline contra-indication

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
progression free survivalat 18 months
Secondary Outcome Measures
NameTimeMethod
progression free survivalat 24 months
rate of over grade 2 toxicitiesat the first and second courses of chemotherapy (day 21 and day 42)
determination of both molecular subtypes GCB and ABCat 24 months

according DASL technology (c-DNA mediated annealing selection extension and ligation)

Trial Locations

Locations (1)

Centre Henri Becquerel

🇫🇷

Rouen, France

Centre Henri Becquerel
🇫🇷Rouen, France
© Copyright 2025. All Rights Reserved by MedPath